Standard Biotools (LAB) Liabilities from Discontinued Operations (2024 - 2025)
Standard Biotools' (LAB) quarterly Liabilities from Discontinued Operations came in at 25633000.0 in Q4 2025, up 23.21% year-on-year from 20804000.0 in Q4 2024, and up 15.39% on a QoQ basis from 22214000.0 in Q3 2025.
Standard Biotools (LAB) Liabilities from Discontinued Operations (2024 - 2025) Analysis & Trends
Standard Biotools (LAB) has 2 years of Liabilities from Discontinued Operations data on file, last reported at 25633000.0 in Q4 2025.
- On a quarterly basis, Liabilities from Discontinued Operations rose 23.21% year-over-year to 25633000.0 in Q4 2025; TTM through Dec 2025 was 25633000.0, a 23.21% increase from a year earlier, with the FY2025 full-year figure at 25633000.0, up 23.21% from the prior year.
- Liabilities from Discontinued Operations for Q4 2025 stood at 25633000.0, up from 22214000.0 in the prior quarter.
- Over the last five years, Liabilities from Discontinued Operations for LAB reached as high as 25633000.0 in Q4 2025 and fell as low as 17984000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.47 Bn | 176.17 Bn | 6.27 Bn |
| 2 | Stryker | 128.89 Bn | 126.01 Bn | 3.81 Bn |
| 3 | Medtronic | 108.71 Bn | 99.49 Bn | 6.41 Bn |
| 4 | Boston Scientific | 68.50 Bn | 67.05 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 48.59 Bn | 44.92 Bn | 1.29 Bn |
| 6 | Dexcom | 28.40 Bn | 27.29 Bn | 750.30 Mn |
| 7 | GE HealthCare Technologies | 28.34 Bn | 26.06 Bn | 1.98 Bn |
| 8 | Smith & Nephew | 26.93 Bn | 26.35 Bn | - |
| 9 | Koninklijke Philips | 25.50 Bn | 22.37 Bn | 2.07 Bn |
| 10 | Standard Biotools | 308.97 Mn | -146.21 Mn | 11.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 25.63 Mn |
| Dec 31, 2025 | 25.63 Mn |
| Sep 30, 2025 | 22.21 Mn |
| Sep 30, 2025 | 22.21 Mn |
| Jun 30, 2025 | 17.98 Mn |
| Jun 30, 2025 | 17.98 Mn |
| Dec 31, 2024 | 20.80 Mn |
| Dec 31, 2024 | 20.80 Mn |